Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22053358 | 1.00 | HTR1A (0.68) | HTR1A | |
| Oxalic Acid SCHEMBL12520684 | 0.91 | HTR1A (0.59) | HTR1A | |
| SCHEMBL1987896 | 0.85 | — | — | |
| SCHEMBL1993124 | 0.85 | — | — | |
| SCHEMBL1987897 | 0.85 | — | — | |
| Hydrochloric Acid SCHEMBL1998920 | 0.84 | SLC6A3 (0.60) | — | |
| Hydrochloric Acid SCHEMBL1996273 | 0.84 | SLC6A3 (0.60) | — | |
| SCHEMBL12609760 | 0.84 | — | — | |
| Hydrochloric Acid SCHEMBL1994945 | 0.84 | SLC6A3 (0.60) | — | |
| SCHEMBL12609755 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0846676-B1 | Process for the preparation of aromatic amines from aryl chlorides | AXIVA GMBH (DE) | 2001-02-07 | — | — | EP | claimed |
| CN-117402124-A | Aryl sulfonamide compound and anti-influenza application thereof | 中国医学科学院医药生物技术研究所 | 2024-01-16 | — | — | CN | disclosed |
| CN-112513021-B | ROR gamma antagonist and application thereof in medicines | 广东东阳光药业有限公司 | 2023-06-27 | — | — | CN | disclosed |
| WO-2023078392-A1 | 2-(ARYL-2-YL) MORPHOLINE AND DEUTERATED DERIVATIVE THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海翰森生物医药科技有限公司 | 2023-05-11 | — | — | WO | disclosed |
| CN-112513021-A | ROR gamma antagonist and application thereof in medicine | 广东东阳光药业有限公司 | 2021-03-16 | — | — | CN | disclosed |
| EP-3362446-B1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A MORPHOLINE MOIETY | INDIVIOR UK LTD (GB) | 2020-12-02 | — | — | EP | disclosed |
| EP-3362446-B1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A MORPHOLINE MOIETY | INDIVIOR UK LTD (GB) | 2020-12-02 | — | — | EP | disclosed |
| US-10577361-B2 | Dopamine D3 receptor antagonists having a morpholine moiety | INDIVIOR UK LIMITED (GB) | 2020-03-03 | — | — | US | disclosed |
| US-10577361-B2 | Dopamine D3 receptor antagonists having a morpholine moiety | INDIVIOR UK LIMITED (GB) | 2020-03-03 | — | — | US | disclosed |
| WO-2020011147-A1 | RORγ ANTAGONIST AND APPLICATION THEREOF IN MEDICINE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2020-01-16 | — | — | WO | disclosed |
| WO-2007134958-A1 | THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-11-29 | — | — | WO | disclosed |
| US-20070270433-A1 | Thiazolo-pyrimidine/pyridine urea derivatives | BRINKMAN JOHN A | 2007-11-22 | — | — | US | disclosed |
| WO-2007099059-A1 | USE OF RYLENES AS MARKERS FOR LIQUIDS | BASF SE (DE) | 2007-09-07 | — | — | WO | disclosed |
| EP-1819678-A1 | RYLENE TETRACARBOXYLIC ACID DIIMIDES SUBSTITUTED BY CYCLIC AMINO GROUPS | BASF AKTIENGESELLSCHAFT (DE) | 2007-08-22 | — | — | EP | disclosed |
| WO-2007054470-A1 | USE OF RYLENE DERIVATIVES AS PHOTOSENSITIZERS IN SOLAR CELLS | BASF SE (DE) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007006717-A1 | SUBSTITUTED RYLENE DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 2007-01-18 | — | — | WO | disclosed |
| WO-2006058674-A1 | RYLENE TETRACARBOXYLIC ACID DIIMIDES SUBSTITUTED BY CYCLIC AMINO GROUPS | BASF AKTIENGESELLSCHAFT (DE) | 2006-06-08 | — | — | WO | disclosed |
| EP-0846676-B1 | Process for the preparation of aromatic amines from aryl chlorides | AXIVA GMBH (DE) | 2001-02-07 | — | — | EP | disclosed |
| US-5831128-A | Synthesis of aromatic amines from chloroamatics | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-11-03 | — | — | US | disclosed |
| EP-0846676-A1 | Process for the preparation of aromatic amines from aryl chlorides | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-06-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10577361-B2 | Dopamine D3 receptor antagonists having a morpholine moiety | DRD3, DRD2, SLC6A3 | HTR1A 73/4885 |
| US-20070270433-A1 | Thiazolo-pyrimidine/pyridine urea derivatives | ADORA2B, UTS2R, TBXA2R | HTR1A 570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.